Definium Therapeutics CEO Robert Barrow sells $721,732 in shares
At a glance
- $DFTX today−2.59%last $29.38
- Vs industry peers−1.45 pts6-peer median −1.14% · behind
- Since Sep 4−23.1%from the first trade after the story
- 52-week range180.7% above low$10.47 – $49.70
- In the headline$721,732Amount
- Coverage0 this week1 in 30 days · too few stories to call a pace
Nothing reported about definium across key-person, legal, regulatory, security, operational or financial-integrity risk in three weeks of coverage and 30 days of SEC filings.
Ranges are one standard deviation of volatility around the latest close — about 1 week in 3 moves further. Not a forecast or investment advice.
What it means
- What to watch: This one turns on a concrete figure ($721,732); set it against the recent trend before reading it as a turning point.
- How the stock is trading: $DFTX -2.59% in the latest session.
- Timing: It was published overnight, so the session change shown belongs to a day that had already closed. Market holidays are not detected.
Where the stock stands
Definium Therapeutics ($DFTX) slipped 2.59% to $29.38 in the latest session. Over the past month it is down 10.9%. It now sits 41% under the 52-week high of $49.70 and 181% above the year's low of $10.47. The year's high was 4.7 times its low, which makes double-digit swings fairly routine here.
How much coverage it is getting
This story is more than a month old. Since then Wook has filed one newer story on Definium Therapeutics in the last 30 days. It reads neutral.
The bigger picture
Healthcare stories turn on approvals, trial data and pricing: one FDA decision or trial readout can swing a single drugmaker hard, while drug-pricing policy moves the whole group at once. Wook's supply-chain scanner shows no unusual stress in Health Care today.
What to watch next
For the company's side of it, read its latest SEC filings on the $DFTX page. A US company has to report material news on an 8-K, usually within four business days; foreign issuers use a 6-K. Where several outlets agree is usually the news; where they differ is the angle. To run the numbers yourself, ask Wook AI above about $DFTX: its distance from the high, its last report, or how coverage has changed.
Discussion
No one has weighed in yet. Start the discussion on this story.
What happened after this published
Investing.com published this on September 5, 2026. $DFTX has moved -23.15% ($38.23 to $29.38). Measured from the first print available after publication, against the latest available quote. This comparison does not isolate the story's effect.
